Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
Immunogenicity and Safety of the Booster Dose of Polio Vaccine Immunization Using Sabin IPV or bOPV at Children Aged 4 Years With Different Three Sequential Schedules History by Sabin IPV or bOPV in China
Sponsor: China National Biotec Group Company ltd
Listed as NCT04576910, this PHASE4 trial focuses on Polio and Vaccine Reaction and remains completed. Sponsored by China National Biotec Group Company ltd, it has been updated 6 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Enrolling By Invitation → Completed
-
Sep 2021 — Apr 2022 [monthly]
Enrolling By Invitation PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE4
▶ Show 1 earlier version
-
Nov 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- China National Biotec Group Company ltd
- Zhejiang Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .